1. Introduction {#sec1-molecules-23-03132}
===============

In recent years, pathogenic bacteria and plant viruses targeting agricultural crops have become increasingly difficult to control, leading to enormous losses in worldwide crop production each year. As such, the development of environmentally friendly pesticides with high selectivity, high efficiency, low toxicity, and suitable degradation are important challenges to both chemists and biologists \[[@B1-molecules-23-03132]\]. Natural products and extracts, derived from the biosphere, have been widely applied for use in medicines \[[@B2-molecules-23-03132]\], pesticides \[[@B3-molecules-23-03132],[@B4-molecules-23-03132]\], cosmetics \[[@B5-molecules-23-03132]\], and food products in ancient and modern societies around the world \[[@B6-molecules-23-03132]\]. Recently, many natural products have shown promise as antimicrobials and antivirals \[[@B7-molecules-23-03132]\], including the quercetin, genistein, and silybin, which belong to the flavonoids group of compounds and have demonstrated inhibitory activity against the DNA virus herpes type 1 (HSV-1) and RNA virus parainfluenza type 3 (PI-3) \[[@B8-molecules-23-03132]\]. Consequently, our research has focused on the properties of natural products as a starting point for the design of pesticide molecules.

Myricetin ([Figure 1](#molecules-23-03132-f001){ref-type="fig"}) belongs to a class of natural flavonoids that is widely found in vegetables, fruits, teas, and medicine herbs \[[@B9-molecules-23-03132],[@B10-molecules-23-03132]\]. Over the last decade, many researchers have shown that natural myricetin exhibits various biological activities, including antibacterial \[[@B11-molecules-23-03132]\], antiviral \[[@B12-molecules-23-03132]\], antioxidant \[[@B9-molecules-23-03132],[@B13-molecules-23-03132]\], anti-inflammatory \[[@B14-molecules-23-03132]\], and anticancer \[[@B15-molecules-23-03132],[@B16-molecules-23-03132],[@B17-molecules-23-03132]\] properties. Most of these prior studies have assessed the properties of myricetin itself, but its derivatives have rarely been studied \[[@B18-molecules-23-03132],[@B19-molecules-23-03132],[@B20-molecules-23-03132],[@B21-molecules-23-03132]\]. Recently, in our prior work, some myricetin derivatives bearing 1,3,4-thiadiazole \[[@B18-molecules-23-03132]\], Schiff-base \[[@B20-molecules-23-03132]\], and acid amide \[[@B21-molecules-23-03132]\] moieties were rationally synthesized and assessed for their potential application as novel anticarcinogens and bactericides.

The compound 1,3,4-thiadiazole contains an important nitrogenous pharmacophore and exhibits different biological activities, such as antimicrobial, antidepressant, and anti-tumor activities. The 1,3,4-thiadiazole ring is very weak due to the induction of sulfur atoms, which makes it easy for it to unlink in alkaline aqueous solutions; however, it is relatively stable in acidic aqueous solutions \[[@B22-molecules-23-03132]\]. The ring readily reacts with a nucleophile to generate diverse derivatives due to its electronic state \[[@B23-molecules-23-03132]\]. Commercial bactericides and antivirals bearing 1,3,4-thiadiazoles have been developed and are widely available, and these include the agricultural bactericidal agents Bismerthiazol and Thiodiazole copper ([Figure 1](#molecules-23-03132-f001){ref-type="fig"}).

Based on these considerations, we designed and synthesized a series of novel myricetin derivatives containing amide, thioether, and 1,3,4-thiadiazole moieties. The derivatives were evaluated via turbidimetry tests and screened against three plant pathogens *Xanthomonas citri* (*Xac*), *Ralstonia solanacearum* (*Rs*), and *Xanthomonas oryzae pv. Oryzae* (*Xoo*). In addition, the ability of these compounds to inhibit tobacco mosaic virus (TMV) was also evaluated in vivo via the half-leaf method at 500 μg/mL, with the commercial antiviral Ribavirin serving as a positive control ([Figure 1](#molecules-23-03132-f001){ref-type="fig"}).

2. Results and Discussion {#sec2-molecules-23-03132}
=========================

2.1. Chemistry {#sec2dot1-molecules-23-03132}
--------------

The synthesis protocol was divided into five steps ([Scheme 1](#molecules-23-03132-sch001){ref-type="scheme"}). Firstly, 2-amino-5-mercapto-1,3,4-thiadiazole (intermediate **1**) was obtained according to the previously reported method \[[@B24-molecules-23-03132]\]. Secondly, intermediates **2a**--**2p** were synthesized from intermediate **1** and various benzyl chlorides via substitution reaction. Thirdly, the intermediates **3a**--**3p** were synthesized via a substitution reaction by treating intermediates **2a**--**2p** with chloroacetyl chloride in the presence of the base K~2~CO~3~. Fourthly, myricitrin was converted to intermediate **4** by methylation and deglycosidation. Finally, the 3-OH on intermediate **4** underwent a substitution reaction with the halogen atom of intermediates **3a**--**3p** to generate the target compounds **5a**--**5p**.

The structures of all the target compounds (**5a**--**5p**) were verified by ^1^H-NMR, ^13^C-NMR, and HRMS. The spectra data are provided in the experiments below. The ^1^H-NMR results showed that all the aryl protons presented as multiplets at approximately 8.65--6.40 ppm, and the characteristic -O-CH~2~- and -S-CH~2~- groups between the myricetin scaffold and 1,3,4-thiadiazole heterocycle were observed at approximately 4.36--4.91 ppm. In the ^13^C-NMR spectra, the typical shifts near 165--169, 150--155, and 31--32 ppm reveal the presence of -N=C- and C=O, the carbon atoms of the 1,3,4-thiadiazole, and -S-CH~2~- groups.

2.2. Antiviral Activities of the Title Compounds against Plant Pathogens In Vivo {#sec2dot2-molecules-23-03132}
--------------------------------------------------------------------------------

Antibacterial activities of myricetin derivatives containing the amide, thioether, and 1,3,4-oxadiazole moieties (**5a**--**5p**) against the plant pathogens *Xac*, *Rs,* and *Xoo* were evaluated in vitro using a turbidimeter method \[[@B25-molecules-23-03132],[@B26-molecules-23-03132],[@B27-molecules-23-03132]\]. The standard drug Myricetin (MYR) and the commercial bactericides Thiodiazole copper (TC) and Bismerthiazol (BT) were chosen as control agents. The results are shown in [Table 1](#molecules-23-03132-t001){ref-type="table"}. Most of the target compounds exhibited similar or slightly enhanced inhibition activities against the pathogens *Xac*, *Rs,* and *Xoo* at the two concentrations tested (100 and 50 μg/mL).

Among the title compounds, the inhibitory rates of compounds **5a**, **5f**, **5g**, **5h**, **5i,** and **5l** possessed excellent antibacterial activities against *Xac* at 100 μg/mL were 75.7, 75.0, 89.2, 74.3, 89.5, and 75.3%, respectively, which were better than those of the commercial bactericides BT (73.3%) and TC (67.7%). The activities of the above target compounds against *Xac* at 50 μg/mL were 64.3, 60.3, 79.5, 68.3, 68.7, and 55.3% respectively, which were better than those of BT (55.0%) and TC (44.3%). Moreover, the inhibition rates of compounds **5a**, **5e,** and **5i** at 100 μg/mL against *Rs* were 70.4, 68.7, 78.0, and 85.6%, respectively, which exceeded that of the BT (69.7%). Compounds **5c**, **5e,** and **5i** at 50 μg/mL showed 63.4, 60.5, and 64.8% inhibition rates, respectively, which were superior to that of BT (57.6%). Furthermore, the inhibitory activities of all the target compounds at 100 μg/mL against *Xoo* were better than the BT (71.1%) and similar to TC (36.1%). Notably, compound **5i** showed comparable or stronger antibacterial activities against *Xac*, *Rs,* and *Xoo* when compared with the two commercial bactericides. Thus, compound **5i** was regarded as the most promising antibacterial agent and used for further evaluation. According to our previous work on myricetin derivatives containing 1,3,4-thiadiazole \[[@B18-molecules-23-03132]\], when the R group is CH~3~, Ph, 2-CH~3~-Ph, and 4-CH~3~O-Ph, the antibacterial activities against *Xoo* of our present work is better than previous work, when R group is 2,4-diCl-Ph, 4-CH~3~O-Ph, and 2-Cl-thiazolyl, the antibacterial activities against *Rs* is better than previously.

Based on previously described bioassays methods \[[@B28-molecules-23-03132]\], some of the compounds with excellent antibacterial activities were tested at five halved concentrations (100, 50, 25, 12.5, and 6.25 μg/mL) in order to obtain their corresponding EC~50~ values. The screening results are shown in [Table 2](#molecules-23-03132-t002){ref-type="table"}. All of the tested compounds exhibited better antibacterial activities against the pathogens *Xac* and *Rs* when compared with BT and TC. In addition, compounds **5e**, **5f,** and **5i** exhibited EC~50~ values of 34.0, 44.9, and 31.2 μg/mL, respectively, which were better than BT and TC (45.3 and 105.4 μg/mL, respectively). Compared with previous work \[[@B18-molecules-23-03132]\], when the R group is CH~3~, 2-Cl-Ph, 2,4-diCl-Ph, and 1,3,4-thiadiazole myricetin derivatives exhibited excellent inhibitory effect on *Rs* at low concentrations.

2.3. Antiviral Activities of the Title Compounds against TMV In Vivo {#sec2dot3-molecules-23-03132}
--------------------------------------------------------------------

At the concentration of 500 μg/mL, the antiviral activities of the target compounds **5a**−**5p** were tested in vivo against TMV using the half-leaf method \[[@B7-molecules-23-03132],[@B29-molecules-23-03132]\], and the results are listed in [Table 3](#molecules-23-03132-t003){ref-type="table"}. For comparison, the commercial antiviral agent ribavirin (RBV) was chosen as the positive control for TMV. The results indicated that compounds **5a**--**5p** showed various degrees of antiviral activities against TMV. Some of these compounds displayed promising curative and inactivation activities, with curative and inactivation rates ranging from 22.3 to 49.9% and 51.5 to 76.7%, respectively. The compounds **5f**, **5g**, **5i**, **5l,** and **5n** showed 42.2, 49.9, 44.2, 45.3**,** and 43.1% curative effects at 500 μg/mL, respectively, which were better than that of RBV (40.6%). Compounds **5g** and **5j** with values of 52.9 and 54.5% showed protective activity against TMV. Moreover, the inactivation activities of all the compounds were similar to that of RBV (71.1%). Compared to our previous work on myricetin derivatives containing 1,3,4-thiadiazole \[[@B18-molecules-23-03132]\], when the R group is Me or 2-F-Ph, the anti-TMV curative activities of present work is better than that of past work. When the R group is CH~3~, 2-F-Ph and 4-CH~3~O-Ph, the anti-TMV protective effect of this work is superior to that of the previous work.

Most target compounds possess better in curative, protective, and inactivation activities against TMV in vivo when compared to RBV. Remarkably, compound **5g** was superior to RBV in regard to all three activities and, thus, was noted as a promising lead compound. As [Figure 2](#molecules-23-03132-f002){ref-type="fig"} shows, the number of local lesion on the leaf treated with either agent (RBV or **5g**) was significantly less than that without treatment. In addition, the area of the smeared with compound was smaller. Regarding the inhibitory mechanism of myricetin on TMV, we are studying it and will report it in subsequent studies. The inhibition rate of the compound was calculated according to the following formula. The average of three replicates were conducted for each sample.

Inhibition rate (%) = \[(local lesion number of control (not treated with compound)---local lesion number smeared with compound)/ local lesion number of control ×100%.

3. Experimental {#sec3-molecules-23-03132}
===============

**Instruments.** The melting points (m.p.) of the title compounds were determined when left untouched on an XT-4-MP apparatus (Beijing Tech Instrument, Beijing, China). The ^1^H-NMR and ^13^C-NMR spectra were recorded on a JEOL-ECX 500 NMR spectrometer (JEOL, Tokyo, Japan) at ambient temperature operating at 500 MHz for ^1^H-NMR and 126 MHz for ^13^C-NMR, using CDCl~3~ or DMSO-*d*~6~ or (CD~3~)~2~CO as solvents and TMS as an internal standard. Chemical shifts were given in δ relative to TMS. The HRMS spectrogram was performed on a Thermo Scientific Q Exactive (Thermo, Waltham, MA, USA). Unless noted, all reagents were of analytical grade or chemically pure and purchased from Tansoole (Shanghai, China). All anhydrous solvents were dried and purified immediately prior to use in accordance with standard techniques.

3.1. Chemistry {#sec3dot1-molecules-23-03132}
--------------

### 3.1.1. Synthesis Procedure for Intermediate **1** {#sec3dot1dot1-molecules-23-03132}

Intermediate **1** was synthesized as detailed in a prior report \[[@B30-molecules-23-03132]\]. A mixture of CS~2~ (120 mmol), anhydrous K~2~CO~3~ (50 mmol), and thiosemicarbazide (100 mmol) in absolute ethanol (120 mL) was stirred under reflux for one hour and then further heated on a steam bath for four hours. Upon completion of the reaction (as indicated by TLC), the solvent was removed, and the residue was dissolved in water, after dropwise addition of 10% HCl, to afford a white solid. The solid was filtered and washed with cold water. Then, the crude product was filtered, washed, and dried to obtain 5-amino-1,3,4-thiadiazole-2-thiol (1) 10.64 g with a 80% yield. m.p. 234--236 °C (References 233 °C \[[@B30-molecules-23-03132]\]).

### 3.1.2. General Procedure for Preparation of Intermediates **2a**--**6p** {#sec3dot1dot2-molecules-23-03132}

Intermediate **2** was synthesized as detailed in a prior report \[[@B31-molecules-23-03132]\] with minor modification. Intermediate **1** (3.8 mmol) and triethylamine (7.6 mmol) were added into 30 mL of pyridine. The mixture was incubated ambient temperature for 0.5 h. Then, bromoethane (3.9 mmol) was added to the reaction system and the mixture was treated at room temperature for four h. After the reaction was completed (as indicated by TLC), 100 mL of deionized water was added to the mixture and left to stand for 10 min. The mixture was then filtered, and the solid was washed with water and subsequently dried under vacuum. Intermediate **2a** was obtained 0.55 g at a yield of 89%. m.p. 136--137 °C. Intermediates **2b**--**2p** were prepared following a similar procedure.

### 3.1.3. General Procedure for Preparation of Intermediates **3a**−**3p** {#sec3dot1dot3-molecules-23-03132}

Compounds **3a**--**3p** were synthesized according to known methods \[[@B32-molecules-23-03132]\]. K~2~CO~3~ (4.5 mmol) were added to a solution of intermediate **2a** (1.8 mmol) in dichloromethane (30 mL). The resulting mixture was then stirred at room temperature for 30 min. Next, a solution prepared by dissolving chloroacetyl chloride (2.7 mmol) in 5 mL dichloromethane was added to the reaction system in a drop wise fashion. The mixture was then stirred at ambient temperature for a further eight hours. After completion of the reaction, the mixture was refluxed for 30 min, and the solvent was removed under reduced pressure. Then, water (20 mL) was added to the mixture to afford a white solid, which was filtered and recrystallized from methanol/water (1:3/*v*:*v*). Intermediate **3a** was obtained 0.34 g with a yield of 77%. m.p. 166--168 °C. Following a similar procedure, intermediates **3b**--**3p** were prepared.

### 3.1.4. General Procedure for Preparation of Intermediate **4** {#sec3dot1dot4-molecules-23-03132}

Preparation of the intermediate **4** has been previously described \[[@B19-molecules-23-03132]\]. The mixture of myricitrin (10 mmol), CH~3~I (130 mmol), and K~2~CO~3~ (12 mmol) was dissolved in DMF (60 mL), and stirred at 40 °C for two days until the reaction was complete (as indicated by TLC analysis). The reaction mixtures were then filtered, and the filtrate was dissolved in 100 mL water and finally extracted three times with dichloromethane (30 mL × 3), combined the dichloromethane, and concentrated under reduced pressure. The concentrated solution was diluted with 40 mL of absolute ethanol, stirred, and refluxed for one hour. The concentrated hydrochloric acid (9 mL) was slowly added to the above obtained for two hours in reflux. The solid was precipitated from the clear solution. After cooling to room temperature, the reaction mixture was filtered, and the obtained solid product was dried at 40 °C for two hours. Intermediate **4** was obtained 2.38 g at a yield of 75%. m.p. 228--230 °C (References 227--229 °C \[[@B19-molecules-23-03132]\]).

### 3.1.5. General Procedure for Preparation of Title Compounds **5a**−**5p** {#sec3dot1dot5-molecules-23-03132}

K~2~CO~3~ (2.1 mmol) was added to a solution of intermediate **4** (0.7 mmol) in DMF (10 mL). The mixture was stirred at room temperature for 0.5 h. Then, a solution prepared by dissolving intermediate **3a** (0.7 mmol) in five mL DMF was added to the reaction system in a dropwise fashion. The reaction mixture was then allowed to stand at 105 °C for four h. Upon completion of the reaction as indicated by TLC (ethyl acetate/methyl alcohol, 15:1/*v*:*v*), the mixture was diluted with water (100 mL) and extracted with dichloromethane (30 mL × 3). The combined dichloromethane extracts were dried over anhydrous Na~2~SO~4~, filtered, concentrated in vacuo, and the crude product was purified by column chromatography (silica gel) using ethyl acetate/methanol (10:1/*v*:*v*) as the eluent to afford a pure target compound. Compound **5a** was obtained 0.31 g at a yield of 75%. Compounds **5b**--**5p** were obtained by the same method. Representative data regarding **5a** are listed below. Data for compounds **5b**--**5p** are given in the [Supporting Information](#app1-molecules-23-03132){ref-type="app"}.

*5,7-Dimethoxy-2-(3,4,5-trimethoxyphenyl)-3-O-(N-(5-((ethyl)thio)-1,3,4-thiadiazol-2-yl) acetamido-2-yl)-4H-chromen-4-one* (**5a**). White solid; yield: 75%; m.p. 223--225 °C; ^1^H-NMR (500 MHz, CDCl~3~) δ: 12.71 (s, 1H, NH), 7.24 (s, 2H, Ar-H), 6.54 (d, *J* = 2.2 Hz, 1H, Ar-H), 6.40 (d, *J* = 2.2 Hz, 1H, Ar-H), 4.48 (s, 2H, O-CH~2~), 3.98 (s, 3H, OCH~3~), 3.96 (s, 3H, OCH~3~), 3.94 (s, 6H, OCH~3~), 3.93 (s, 3H, OCH~3~), 3.27 (q, *J* = 7.4 Hz, 2H, S-CH~2~), 1.44 (t, *J* = 7.4 Hz, 3H, CH~3~); ^13^C-NMR (126 MHz, CDCl~3~) δ: 174.27, 167.50, 164.93, 161.18, 160.43, 158.98, 158.03, 154.18, 153.48, 140.82, 140.77, 124.62, 108.56, 105.82, 96.36, 92.62, 72.53, 61.09, 56.49, 55.98, 28.71, 14.72. ESI-HRMS (*m*/*z*), calcd. for C~26~H~27~N~3~O~9~S~2~ \[M + H\] ^+^ 590.1262, found 590.1252.

3.2. Biological Assays {#sec3dot2-molecules-23-03132}
----------------------

The antibacterial activities of compounds **5a**--**5p** against *Xac* (Shanghai Jiao Tong University, China), *Rs* (Guizhou University, China), and *Xoo* (Nanjing Agricultural University, China) were evaluated based on the turbidimeter test \[[@B25-molecules-23-03132],[@B26-molecules-23-03132],[@B27-molecules-23-03132]\]. The test compounds were dissolved in 150 μL of dimethyl sulfoxide (DMSO) and diluted with water containing Tween−20 (0.1%) to obtain final concentrations of 100 and 50 μg/mL. Pure DMSO in sterile distilled water served as a blank control, whereas TC and BT served as positive controls. Approximately one mL of liquid sample was added to the nontoxic nutrient broth (NB; three g of beef extract, five g of peptone, one g of yeast powder, 10 g of glucose, and one L of distilled water, Adjust pH = 7.0--7.2 with 10% NaOH) liquid medium in four mL tubes. Then, approximately 40 *μ*L of NB containing bacterium *Xac*/*Rs*/*Xoo* was added to five mL of solvent NB containing the test compounds or TC/BT. The above test tubes were incubated at 30 ± 1 °C with continuous shaking at 180 rpm for 1--3 days. Bacterial growth was monitored with a spectrophotometer by measuring the optical density at 600 nm (OD~600~), given by corrected turbidity values = OD~bacterium~ − OD~no\ bacterium~. The relative inhibitory rate (*I*%) of the circle mycelium compared with a blank assay was calculated as follows: *I* = (*C*~tur~ − *T*~tur~)/*C*~tur~ × 100%. The *C*~tur~ represents the corrected turbidity value of bacterial growth in untreated NB (blank control), and *T*~tur~ is the corrected turbidity value of bacterial growth in treated NB. Similarly, the excellent antibacterial activities of the target compounds and TC/BT were further assessed against the bacteria *Xac*, *Rs*, and *Xoo* at five double-declining concentrations (100, 50, 25, 12.5, and 6.25 μg/mL) to obtain their EC~50~ values, which were statistically determined using probit analysis within the software package SPSS 17.0. The listed EC~50~ values in [Table 2](#molecules-23-03132-t002){ref-type="table"} are the average of three trials.

The curative, protection, and inactivation activities against TMV of the target compounds were tested using previously reported methods \[[@B7-molecules-23-03132],[@B29-molecules-23-03132]\]. The commercial compound RBV was used as a comparison and an average of three replications were conducted for each sample.

4. Conclusions {#sec4-molecules-23-03132}
==============

In conclusion, a series of myricetin derivatives containing amide, 1,3,4-oxadiazole, and thioether moieties were developed as potential antibacterial and antiviral agents, and sixteen novel compounds were synthesized. The bioassay results indicated that some of the target compounds possessed excellent antibacterial activities against the plant pathogens *Xoo*, *Rs,* and *Xoo*. For example, compounds **5a**, **5f**, **5g**, **5h**, **5i**, and **5l** showed strong antibacterial activity against *Xac*, with the EC~50~ values of 11.5--27.3 μg/mL, which are significantly better than the commercial bactericides BT (34.7 μg/mL) and TC (41.1% μg/mL). An anti-TMV activity test for the target compounds was performed, and among these compounds, the curative, protection and inactivation activities of **5g** were 49.9%, 52.9%, and 73.3%, respectively, which are better than that of the commercial antiviral RBV (40.6, 51.1, and 71.1%, respectively). It is noteworthy that most of the myricetin derivatives obtained by derivatization had better antibacterial and antiviral activities than those of myricetin. The above studies showed that myricetin derivatives containing amide, 1,3,4-oxadiazole, and thioether moieties could serve as promising candidates for the development of new and more efficient agricultural bactericides against bacterial pathogens and plant viruses.

On the basis of the previous work \[[@B18-molecules-23-03132]\], the hydrophilic amide structure was introduced to improve the water-solubility of target compounds and enrich the structure type and quantity of myricetin derivatives. Extending the linking group between myricetin and the 1,3,4-thiadiazole also made the molecules more flexible and provided some preliminary structure-activity relationships. The bioassays indicated that 1,3,4-thiadiazole and myricetin could not bind to the target protein of *Rs*, *Xoo,* and TMV by extending the linking group between 1,3,4-thiadiazole and myricetin.

**Sample Availability:** Samples of the compounds **5a**--**5p** are available from the authors.

The supplementary materials containing the yield relationship, ^1^H-NMR, ^13^C-NMR, HRMS dates and spectra of the title compounds **5a**--**5p** are available online.

###### 

Click here for additional data file.
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molecules-23-03132-t001_Table 1

###### 

Antibacterial activities of the target compounds (**5a--5p**) against plant pathogenic bacteria in vitro.

  Compd.    Inhibition Rate ^a^/%                                                       
  --------- ----------------------- ------------ ------------ ------------ ------------ ------------
  **5a**    75.7 ± 5.3              64.3 ± 3.1   70.4 ± 7.5   50.2 ± 6.5   59.1 ± 2.3   54.4 ± 2.9
  **5b**    54.7 ± 1.9              53.5 ± 1.1   41.5 ± 7.5   16.4 ± 0.9   51.7 ± 2.6   44.2 ± 3.4
  **5c**    51.3 ± 4.9              18.9 ± 2.6   68.7 ± 6.5   63.4 ± 4.6   62.7 ± 2.8   44.1 ± 6.7
  **5d**    39.3 ± 1.4              34.7 ± 1.7   35.3 ± 3.0   37.0 ± 2.0   59.1 ± 2.6   58.0 ± 1.7
  **5e**    44.4 ± 2.8              15.2 ± 5.3   78.0 ± 1.5   60.5 ± 3.1   69.8 ± 8.2   62.0 ± 3.0
  **5f**    75.0 ± 5.9              60.3 ± 3.6   33.5 ± 9.3   3.0 ± 1.7    68.4 ± 3.5   50.4 ± 2.5
  **5g**    89.2 ± 1.9              79.5 ± 1.6   29.7 ± 0.8   20.6 ± 0.7   65.6 ± 5.8   61.4 ± 1.5
  **5h**    74.3 ± 2.8              68.3 ± 5.6   41.5 ± 0.3   38.5 ± 2.0   69.5 ± 1.7   33.7 ± 2.8
  **5i**    89.5 ± 6.5              68.7 ± 2.7   85.6 ± 4.9   64.8 ± 1.7   78.3 ± 6.9   53.0 ± 1.8
  **5j**    41.5 ± 4.1              29.2 ± 3.0   66.3 ± 2.0   59.6 ± 4.9   44.4 ± 5.2   36.9 ± 3.9
  **5k**    73.5 ± 6.7              51.6 ± 2.7   28.9 ± 2.1   25.6 ± 1.1   48.3 ± 2.8   47.5 ± 2.5
  **5l**    75.3 ± 5.3              55.3 ± 4.1   34.9 ± 4.5   31.2 ± 4.9   54.1 ± 4.0   36.8 ± 1.7
  **5m**    72.6 ± 4.8              35.2 ± 1.7   41.4 ± 7.3   34.7 ± 5.8   55.3 ± 2.8   50.2 ± 1.0
  **5n**    55.3 ± 2.1              47.9 ± 1.4   52.5 ± 2.9   49.9 ± 4.2   44.8 ± 0.7   43.8 ± 3.4
  **5o**    55.6 ± 7.7              46.8 ± 7.0   33.2 ± 2.3   8.3 ± 0.8    77.6 ± 4.3   42.3 ± 1.6
  **5p**    67.4 ± 6.8              51.1 ± 7.0   36.7 ± 4.0   35.0 ± 1.3   47.8 ± 7.5   31.8 ± 2.6
  MYR ^b^   40.7 ± 4.8              31.1 ± 3.0   57.1 ± 7.5   44.2 ± 3.4   68.5 ± 8.0   53.2 ± 9.4
  BT ^c^    73.3 ± 8.2              55.0 ± 4.5   69.7 ± 1.9   57.6 ± 3.1   71.1 ± 3.8   36.5 ± 2.9
  TC ^c^    67.7 ± 3.7              44.3 ± 4.0   35.3 ± 3.8   18.9 ± 4.4   36.1 ± 1.3   35.8 ± 2.1

^a^ Average of three replicates. ^b^ The lead compound of myricetin. ^c^ The commercial agricultural bactericides, Bismerthiazol, and Thiodiazole copper were used in a comparison of antibacterial activity.

molecules-23-03132-t002_Table 2

###### 

EC~50~ values of the title compounds against plant pathogenic bacteria in vitro.

  Bacteria   Compd.        R                      Toxic Regression Equation   r             EC~50~/(μg/mL)
  ---------- ------------- ---------------------- --------------------------- ------------- ----------------
  *Xac*      **5a**        CH~3~                  y = 1.2309x + 3.2852        0.9814        24.7 ± 2.7
  **5f**     2-F-Ph        y = 1.1496x+3.3598     0.9978                      26.7 ± 1.3    
  **5g**     4-F-Ph        y = 1.3129x + 3.5997   0.9928                      11.5 ± 1.8    
  **5h**     2-CH~3~-Ph    y = 1.3011x + 3.1703   0.9882                      25.5 ± 3.2    
  **5i**     3-CH~3~-Ph    y = 1.5172x + 3.0628   0.9740                      18.9 ± 2.6    
  **5l**     4-CF~3~-Ph    y = 1.0060x + 3.5803   0.9869                      27.3 ± 2.9    
  BT ^a^     \-            y = 1.2497x + 3.0744   0.9755                      34.7 ± 1.3    
  TC ^a^     \-            y = 1.1587x + 3.1306   0.9920                      41.1 ± 3.7    
  *Rs*       **5a**        CH~3~                  y = 1.0299x + 3.4622        0.9675        31.3 ± 2.5
  **5c**     2-Cl-Ph       y =0.7749x + 3.8771    0.9861                      28.1 ± 4.2    
  **5e**     2,4-diCl-Ph   y = 1.7574x + 2.1963   0.9954                      39.4 ± 3.4    
  **5i**     3-CH~3~-Ph    y = 2.0968x + 1.7437   0.9873                      35.7 ± 1.6    
  BT ^a^     \-            y = 1.2725x + 2.6703   0.9839                      67.2 ± 2.2    
  TC ^a^     \-            y = 1.2681x + 2.3203   0.9927                      112.5 ± 4.7   
  *Xoo*      **5e**        2,4-diCl-Ph            y = 1.3410x + 2.9457        0.9951        34.0 ± 3.2
  **5f**     2-F-Ph        y = 1.3885x + 2.7900   0.9839                      44.9 ± 3.5    
  **5h**     2-CH~3~-Ph    y = 2.0971x + 1.1978   0.9918                      65.0 ± 2.1    
  **5i**     3-CH~3~-Ph    y = 1.3586x + 2.9710   0.9891                      31.2 ± 2.4    
  **5o**     4-CF~3~-Ph    y = 1.8004x + 1.9332   0.9792                      50.5 ± 5.7    
  BT ^a^     \-            y = 1.6145x + 1.7430   0.9887                      45.3 ± 3.0    
  TC ^a^     \-            y = 1.8721x + 1.8993   0.9830                      105.1 ± 4.6   

^a^ The commercial agricultural antibacterial agents Thiodiazole copper (TC) and Bismerthiazol (BT) were used as control agents.

molecules-23-03132-t003_Table 3

###### 

Antiviral activities of the test compounds against TMV in vivo at 500 μg/mL.

  Compd.    R                  Inhibition Rate ^a^/%                
  --------- ------------------ ----------------------- ------------ ------------
  **5a**    CH~3~              38.0 ± 6.3              40.0 ± 6.9   53.6 ± 5.4
  **5b**    Ph                 26.0 ± 4.9              36.0 ± 6.0   71.5 ± 5.1
  **5c**    2-Cl-Ph            27.1 ± 4.1              40.8 ± 7.1   72.9 ± 5.1
  **5d**    4-Cl-Ph            35.6 ± 4.9              42.2 ± 7.3   62.0 ± 2.8
  **5e**    2,4-diCl-Ph        22.3 ± 1.8              43.2 ± 4.6   76.7 ± 3.5
  **5f**    2-F-Ph             42.2 ± 8.9              49.2 ± 8.4   61.2 ± 5.9
  **5g**    4-F-Ph             49.9 ± 5.0              52.9 ± 5.2   73.3 ± 2.8
  **5h**    2-CH~3~-Ph         31.0 ± 6.4              34.7 ± 5.7   58.1 ± 4.6
  **5i**    3-CH~3~-Ph         44.2 ± 5.3              45.3 ± 7.2   57.0 ± 4.6
  **5j**    4-CH~3~O-Ph        30.6 ± 1.0              54.5 ± 5.7   63.5 ± 4.9
  **5k**    3-CF~3~-Ph         39.9 ± 4.2              46.4 ± 5.9   60.2 ± 3.9
  **5l**    4-CF~3~-Ph         45.3 ± 4.1              49.9 ± 7.3   59.5 ± 6.2
  **5m**    3-pyridyl          33.2 ± 4.8              32.2 ± 8.8   52.5 ± 5.5
  **5n**    4-pyridyl          43.1 ± 3.3              36.1 ± 8.6   62.6 ± 3.3
  **5o**    2-Cl-5-thiazolyl   33.8 ± 7.6              44.8 ± 5.9   65.3 ± 2.7
  **5p**    4-NO~2~-Ph         35.9 ± 3.7              47.7 ± 2.4   64.6 ± 4.1
  MYR ^b^   \-                 36.7 ± 6.3              42.3 ± 6.5   51.5 ± 3.7
  RBV ^c^   \-                 40.6 ± 2.5              51.1 ±2.3    71.1 ± 4.2

^a^ Average of three replicates. ^b^ The lead compound of myricetin(MYR). ^c^ The commercial antiviral agent Ribavirin (RBV).

[^1]: These authors contributed equally to this work.
